Aspeya operates as a separate company under the ownership of Philip Morris International and benefits from access to the oral technology platform of Fertin Pharma, a contract development and manufacturing organization (CDMO) that is a wholly owned subsidiary of Aspeya. Fertin Pharma develops and manufactures innovative oral and intra-oral delivery systems.
Products, services, technology
We’re applying our expertise to innovate in the field of wellness and healthcare in four areas of focus:
- Cannabinoids
- Inhaled therapeutics
- Nicotine replacement therapy (NRT)
- Consumer health
Cooperation possibilities
Innovative pharmaceutical and consumer life sciences products, Innovative life sciences products & technologies, CDMO business for inhaled, oral, intra-oral products and delivery systems, Licensing and partnerships: innovative products and technology platforms.
- https://www.aspeya.com/
- +41 78 266 62 58
- Send an email
- Begoña Carreño
Some insights
We are driven by the exciting and unique goal of revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.